Jonathan Friedberg: Comparison of Ide-cel Versus Cilta-cel in Relapsed/Refractory Multiple Myeloma
Jonathan Friedberg, Director at Wilmot Cancer Institute, posted on X:
“The results of this analysis will inform personalized treatment decision-making in patients with multiple myeloma eligible for CAR T-cell therapy and confirm the value of real-world data in generating practice-informing data.”
Title: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Authors: Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Christopher Ferreri, Omar Castaneda, James A. Davis, Evguenia Bhurtel, Joseph McGuirk, Charlotte Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud Gaballa, Megan M. Herr, Peter Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori Maringanti, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W. Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara L. Freeman, Frederick L. Locke, Peter Voorhees, Larry D. Anderson Jr, Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, and Surbhi Sidana.
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Jonathan Friedberg.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023